CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer's disease ligands

Greven, Jessica A., Wydra, Joshua R., Greer, Rory A., Zhi, Cynthia, Price, David A., Svoboda, Jordyn D., Camitta, Christopher L. M., Washington, Mya, Leung, Daisy W., Song, Yuhua, Alexander-Brett, Jen, Brett, Tom J.·2025·Molecular Neurodegeneration
DOI 10.1186/s13024-024-00795-9PMC PMC11721465

Published version of a preprint

Open this paper in CoChat — free account

Abstract

TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have been identified, little is known regarding the structural details of how they engage. To better understand this, we created a protein library of 28 different TREM2 variants that could be used to map interactions with various ligands using biolayer interferometry. The variants are located in previously identified putative binding surfaces on TREM2 called the hydrophobic site, basic site, and site 2. We found that mutations to the hydrophobic site ablated binding to apoE4 and TDP-43. Competition binding experiments indicated that apoE4 and oAβ42 share overlapping binding sites on TREM2. In contrast, binding to C1q was disrupted most strongly by mutations to the basic site, including R46, with some mutations to the hydrophobic site also attenuating binding, thus suggesting a broader mediation of binding across the two sites. Supporting this, competition experiments indicated that C1q binding could be blocked by both apoE and oAβ42. TREM2 binding to IL-34 was mediated by the basic site at a surface centering on R76. Competition binding experiments validated the unique site for IL-34, showing little to no competition with either oAβ42 or apoE4. However, competition experiments between C1q and IL34 suggest that the ligands compete for binding at the basic site. Altogether, our results suggest that TREM2 utilizes the hydrophobic site (consisting of CDR1, CDR2, and CDR3) as a common site to engage multiple ligands, and uses distinct basic sites to engage others. Our findings imply that pharmaceutical strategies targeting these surfaces might be effective to modulate TREM2 functions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-024-00795-9

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Deczkowska A, Weiner A, Amit I. The Physiology, Pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181:1207–17. · DOI · Paper page
  2. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. · DOI · Paper page
  3. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16. · DOI · Paper page
  4. Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun. 2019;10:1365. · DOI · Paper page
  5. Belsare KD, Wu H, Mondal D, Bond A, Castillo E, Jin J, Jo H, Roush AE, Pilla KB, Sali A et al. Soluble TREM2 inhibits secondary nucleation of Abeta fibrillization and enhances cellular uptake of fibrillar abeta. Proc Natl Acad Sci U S A 2022, 119. · DOI · Paper page
  6. Kober DL, Stuchell-Brereton MD, Kluender CE, Dean HB, Strickland MR, Steinberg DF, Nelson SS, Baban B, Holtzman DM, Frieden C et al. Functional insights from biophysical study of TREM2 interactions with apoE and Abeta(1–42). Alzheimers Dement 2020. · DOI
  7. Vilalta A, Zhou Y, Sevalle J, Griffin JK, Satoh K, Allendorf DH, De S, Puigdellivol M, Bruzas A, Burguillos MA, et al. Wild-type sTREM2 blocks abeta aggregation and neurotoxicity, but the Alzheimer’s R47H mutant increases abeta aggregation. J Biol Chem. 2021;296:100631. · DOI · Paper page
  8. Jendresen C, Arskog V, Daws MR, Nilsson LN. The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. J Neuroinflammation. 2017;14:59. · DOI · Paper page
  9. Xie M, Liu YU, Zhao S, Zhang L, Bosco DB, Pang YP, Zhong J, Sheth U, Martens YA, Zhao N, et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nat Neurosci. 2022;25:26–38. · DOI · Paper page
  10. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–3. · DOI · Paper page
  11. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL 3rd, Schneider JA, Kretzschmar HA, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171:227–40. · DOI
  12. Xie X, Zhang W, Xiao M, Wei T, Qiu Y, Qiu J, Wang H, Qiu Z, Zhang S, Pan Y, et al. TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice. Blood. 2023;141:3184–98.
  13. Chhetri G. Emerging roles of IL-34 in neurodegenerative and neurological infectious disease. Int J Neurosci. 2023;133:660–71. · DOI
  14. Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife 2016, 5. · DOI · Paper page
  15. Aricescu AR, Lu W, Jones EY. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62:1243–50. · DOI
  16. Bernhofer M, Dallago C, Karl T, Satagopam V, Heinzinger M, Littmann M, Olenyi T, Qiu J, Schutze K, Yachdav G, et al. PredictProtein - Predicting protein structure and function for 29 years. Nucleic Acids Res. 2021;49:W535–40. · DOI
  17. Qiu J, Bernhofer M, Heinzinger M, Kemper S, Norambuena T, Melo F, Rost B. ProNA2020 predicts protein-DNA, protein-RNA, and protein-protein binding proteins and residues from sequence. J Mol Biol. 2020;432:2428–43. · DOI
  18. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157:105–32. · DOI
  19. Jacchieri SG, Torquato R, Brentani RR. Structural study of binding of flagellin by toll-like receptor 5. J Bacteriol. 2003;185:4243–7. · DOI
  20. Ma X, Lin WY, Chen Y, Stawicki S, Mukhyala K, Wu Y, Martin F, Bazan JF, Starovasnik MA. Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure. 2012;20:676–87. · DOI
  21. Greven JA, Brett TJ. Production of eukaryotic glycoproteins for structural and functional studies using Expi293F cells. Curr Protoc. 2022;2:e512. · DOI
  22. Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD et al. High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med 2018, 10. · DOI
  23. Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation. Biochemistry. 2014;53:6323–31. · DOI · Paper page
  24. PrabhuDas MR, Baldwin CL, Bollyky PL, Bowdish DME, Drickamer K, Febbraio M, Herz J, Kobzik L, Krieger M, Loike J, et al. A Consensus definitive classification of scavenger receptors and their roles in Health and Disease. J Immunol. 2017;198:3775–89. · DOI
  25. Dean HB, Roberson ED, Song Y. Neurodegenerative Disease-Associated variants in TREM2 destabilize the apical ligand-binding region of the Immunoglobulin Domain. Front Neurol. 2019;10:1252. · DOI
  26. Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE, Colonna M. Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13:381–7. · DOI · Paper page
  27. Dean HB, Greer RA, Yang SZ, Elston DS, Brett TJ, Roberson ED, Song Y. Multimerization of TREM2 is impaired by Alzheimer’s disease-associated variants. Alzheimers Dement. 2024;20:6332–50. · DOI
  28. Feuerbach D, Schindler P, Barske C, Joller S, Beng-Louka E, Worringer KA, Kommineni S, Kaykas A, Ho DJ, Ye C, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after histidine 157. Neurosci Lett. 2017;660:109–14. · DOI
  29. Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, Haass C. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 2017;9:1356–65. · DOI
  30. Del-Aguila JL, Benitez BA, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Farias FHG, Fernandez MV, Ibanez L, Jiang S, et al. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Mol Neurodegener. 2019;14:18. · DOI

Cited by

Sorted by citations

Metadata

Authors
Greven, J. A., Wydra, J. R., Greer, R. A., Zhi, C., Price, D. A., Svoboda, J. D., Camitta, C. L. M., Washington, M., Leung, D. W., Song, Y., Alexander-Brett, J., & Brett, T. J.
ORCID
Brett, Tom J.
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2025-01-09
Volume
20
Issue
1
ISSN
1750-1326
DOI
10.1186/s13024-024-00795-9
PMC
PMC11721465
Cited by
42
References
12
Language
en
Licence
Funders
  • Alzheimer’s Association (AARG-16-441560, ZEN-25-1269507)
  • BrightFocus Foundation (A2022032S)
  • Burroughs Wellcome Fund (CAMS 1014685)
  • National Heart, Lung, and Blood Institute (R01HL152245, R01HL170198)
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI159678, R01AI169850)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review